Home » Market News » DirectorsTalk Highlights » Advances in Analytics for Bioprocessing
Microsaic Systems plc

Advances in Analytics for Bioprocessing

Richard Moseley, Chief Technologist at Microsaic talks to Biopharma International about process analytical technology (PAT) for monitoring and controlling biopharma production processes.

When FDA’s process analytical technology (PAT) initiative was first unveiled, the aim was to have the industry move away from a mindset of “testing quality” at the end of production to instead develop methods that monitor, assess, predict, and control quality from the start of the manufacturing process. PAT tools have facilitated ongoing monitoring and adjustment of bioprocesses to ensure that biologic drug products are produced with high quality, meeting the required specifications all the time.


Founded in 2001, Microsaic Systems plc (LON:MSYS) is a high technology company which develops point-of-need mass spectrometers, designed to improve the efficiency of chemical and biological workflows.

To read the full news article please click here

Receive our exclusive interviews – Enter your email to stay up to date.

Disclaimer: Statements in this article should not be considered investment advice, which is best sought directly from a qualified professional.